File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease

TitleNeurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease
Authors
KeywordsBasal ganglion
Dopamine
Neurodegeneration
Neurokinins
Neuroprotection
Parkinson' disease
Issue Date2004
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdt/index.htm
Citation
Current Drug Targets, 2004, v. 5 n. 2, p. 197-206 How to Cite?
AbstractParkinson's disease (PD) is a serious motor disorder and it is the second most common brain degenerative disease in human. PD is known to be caused by degeneration of dopamine neurons in the substantia nigra but the cause of cell death is largely unknown. Mammalian neurokinins [NKs] are a group of neuropeptides that include substance P (SP; neurokinin-1, NK-1), substance K (SK; NK-2, neurokinin A), and neuromedin K (NK; NK-3; neurokinin B). Their biological effects as neurotransmitters, neuromodulators, or neurotrophic-like factors are mediated by three distinct neurokinin receptors, namely SP receptor (SPR: NK-1 receptor, NK-1R), SKR (NK-2R), and NKR (NK-3R). Several lines of evidence have indicated that neurokinins are implicated in the pathogenesis of PD. First, decreases of SP level and SP-immunoreactivity have been found in nigral and striatal tissues of animals with PD and postmortem PD patients. Second, NKs exert neuroprotective effects on neurons. In addition, NK receptors, namely NK-1 and NK-3 receptors, are abundantly localized in dopaminergic and cholinergic neurons of the basal ganglia, indicating that these neurons are under the physiological regulation of NKs. Moreover, modulation in motor activity occurred in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, PD animal model, after systemic administration of NK receptor agonists. NKs and NK receptors, therefore, might be important molecules that are associated with functions and survival of neurons in the basal ganglia, in particular the dopamine neurons. Further studies should be devoted to elucidate the functional roles of NK systems in (a) the neuropathogenesis and neuroprotection during the course of PD, (b) the efficacy of NK receptor drugs towards PD, and (c) potential therapeutic intervention that targets at the prevention or treatment of PD. © 2004 Bentham Science Publishers Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/81281
ISSN
2015 Impact Factor: 3.029
2015 SCImago Journal Rankings: 1.211
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChen, LWen_HK
dc.contributor.authorYung, KKLen_HK
dc.contributor.authorChan, YSen_HK
dc.date.accessioned2010-09-06T08:15:53Z-
dc.date.available2010-09-06T08:15:53Z-
dc.date.issued2004en_HK
dc.identifier.citationCurrent Drug Targets, 2004, v. 5 n. 2, p. 197-206en_HK
dc.identifier.issn1389-4501en_HK
dc.identifier.urihttp://hdl.handle.net/10722/81281-
dc.description.abstractParkinson's disease (PD) is a serious motor disorder and it is the second most common brain degenerative disease in human. PD is known to be caused by degeneration of dopamine neurons in the substantia nigra but the cause of cell death is largely unknown. Mammalian neurokinins [NKs] are a group of neuropeptides that include substance P (SP; neurokinin-1, NK-1), substance K (SK; NK-2, neurokinin A), and neuromedin K (NK; NK-3; neurokinin B). Their biological effects as neurotransmitters, neuromodulators, or neurotrophic-like factors are mediated by three distinct neurokinin receptors, namely SP receptor (SPR: NK-1 receptor, NK-1R), SKR (NK-2R), and NKR (NK-3R). Several lines of evidence have indicated that neurokinins are implicated in the pathogenesis of PD. First, decreases of SP level and SP-immunoreactivity have been found in nigral and striatal tissues of animals with PD and postmortem PD patients. Second, NKs exert neuroprotective effects on neurons. In addition, NK receptors, namely NK-1 and NK-3 receptors, are abundantly localized in dopaminergic and cholinergic neurons of the basal ganglia, indicating that these neurons are under the physiological regulation of NKs. Moreover, modulation in motor activity occurred in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, PD animal model, after systemic administration of NK receptor agonists. NKs and NK receptors, therefore, might be important molecules that are associated with functions and survival of neurons in the basal ganglia, in particular the dopamine neurons. Further studies should be devoted to elucidate the functional roles of NK systems in (a) the neuropathogenesis and neuroprotection during the course of PD, (b) the efficacy of NK receptor drugs towards PD, and (c) potential therapeutic intervention that targets at the prevention or treatment of PD. © 2004 Bentham Science Publishers Ltd.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cdt/index.htmen_HK
dc.relation.ispartofCurrent Drug Targetsen_HK
dc.subjectBasal ganglionen_HK
dc.subjectDopamineen_HK
dc.subjectNeurodegenerationen_HK
dc.subjectNeurokininsen_HK
dc.subjectNeuroprotectionen_HK
dc.subjectParkinson' diseaseen_HK
dc.titleNeurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's diseaseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1389-4501&volume=5&issue=2&spage=197&epage=206&date=2004&atitle=Neurokinin+peptides+and+neurokinin+receptors+as+potential+therapeutic+intervention+targets+of+basal+ganglia+in+the+prevention+and+treatment+of+Parkinson’s+diseaseen_HK
dc.identifier.emailChan, YS: yschan@hkucc.hku.hken_HK
dc.identifier.authorityChan, YS=rp00318en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2174/1389450043490596en_HK
dc.identifier.pmid15011953-
dc.identifier.scopuseid_2-s2.0-1442302324en_HK
dc.identifier.hkuros92129en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-1442302324&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue2en_HK
dc.identifier.spage197en_HK
dc.identifier.epage206en_HK
dc.identifier.isiWOS:000189287300009-
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridChen, LW=7409444941en_HK
dc.identifier.scopusauthoridYung, KKL=13605496000en_HK
dc.identifier.scopusauthoridChan, YS=7403676627en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats